Person Details

Donna Roy Grogan,

Donna Roy Grogan,, M.D.

Donna Roy Grogan, M.D., has been a director since September 2019. Dr. Grogan, who is now Principal, Grogan Consulting LLC, previously served as chief medical officer of Clementia Pharmaceuticals, Inc. (acquired by Ipsen in April 2019), a biopharmaceutical company innovating new treatments for ultra-rare bone disorders and other diseases. Prior to working at Clementia, Dr. Grogan served as the chief medical officer for several Health Care Venture focused companies including Anexon, Apofore and DecImmune. She previously worked at FoldRx Pharmaceuticals (acquired by Pfizer in October 2010) as chief medical officer. and at Sepracor (now Sunovion) where she was Senior Vice President Clinical Research at her departure. She has made significant contributions to numerous successful NDAs, including Lunestaâ, Xopenex HFAâ, BrovanaTM and most recently the EMA authorization of Vyndaqelâ (tafamidis) for the treatment of the rare neurologic disease Transthyretin Familial Amyloid Polyneuropathy. Dr. Grogan received her B.A. from College of the Holy Cross and earned her M.D. from University of Illinois College of Medicine. Dr. Grogan’s qualifications to sit on the board include her 15 years of experience as a board-certified physician, her leadership in numerous investigational new drug applications and her expertise in the design and execution of clinical programs across multiple therapeutic areas, including rare diseases.